News Update

Healthcare Company to Use IBM's Watson AI in Telemedicine App

News Update
  ()
The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care. read more >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

  ()
Shares of Relmada Therapeutics traded wildly after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100200% higher and the stock was halted several times trading due to extreme price volatility. read more >

Platinum Group Metal Cowboys in Montana

  ()
A small-cap company in Montana is exploring to find out if its property contains "Platreef-style" PGE mineralization. read more >

Target Raised on Gold Miner 'On Track to Meet Overall Guidance'

Research Report
  ()
Q3/19 production totals from the company's various assets are discussed in a CIBC report. read more >
News Update

Drill Results from Nevada Project Show Resource Expansion Potential

News Update
  ()
The company will use these new data in designing the mine and optimizing the prefeasibility study. read more >

Technical Analyst Expects Health Technologies Firm to Break Higher

Contributed Opinion
  ()
Technical analyst Clive Maund outlines the reasons this stock might break higher. read more >

Project Generator Looks to Partner on Alaskan Prospect

Contributed Opinion
  ()
Maurice Jackson of Proven and Probable discusses the latest developments in the Goodpaster District with this company's chief executive and senior geologist. read more >

Prominent Gold Stock at 'Buy Spot'

Contributed Opinion
  ()
Technical analyst Clive Maund's charts explain why he sees this stock as a buy. read more >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

  ()
Shares of Cerecor Inc. traded higher after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. read more >

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company

Contributed Opinion
  ()
Technical analyst Clive Maund believes this stock could gain traction soon. read more >

Expert Investing Ideas

"NTAR as a unique public pure play deserves a higher valuation."

–Lisa Thompson, Zacks Small-Cap Research


"POE hit another high-impact well a little further away, called AA."

–Chen Lin, What Is Chen Buying? What Is Chen Selling?


"GBR completed 14 fences of holes along the LP fault."

–Gwen Preston, The Maven Letter


"Three GBR targets on the LP fault showed similar geology and grade."

–Brien Lundin, Gold Newsletter (Jefferson Financial)


"GSV's South Railroad project has an after-tax NPV5% of $241.5M."

–Brien Lundin, Gold Newsletter (Jefferson Financial)


"ABN is clearly on to a large mineralized system at North Boundary."

–Brien Lundin, Gold Newsletter (Jefferson Financial)


"GBR seems likely to continue providing bullish news on a regular basis."

–Brien Lundin, Gold Newsletter (Jefferson Financial)


"We are maintaining our Market Perform rating on EFR."

–Mark Reichman, Noble Capital Markets


"POE's current assets plus cash should be worth at least CA$3."

–Chen Lin, What Is Chen Buying? What Is Chen Selling?


Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

Explorer a 'Highly Attractive Speculative Play'

Contributed Opinion
  ()
This miner has taken a hit, but technical analyst Clive Maund explains why the stock may be a good buy at current levels. read more >
News Update

Explorer Reports Results for Holes Drilled Between Red Lake Project's Subzones

News Update
  ()
Also, a geochemical survey identifies four new exploration targets. read more >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

  ()
Shares of Reata Pharmaceuticals traded 12% higher after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. read more >

Junior Gold Stock 'On the Up'

Contributed Opinion
  ()
Technical analyst Clive Maund charts a junior explorer and explains why he sees it as a speculative buy. read more >